Time in Range Analysis in Automated Insulin Delivery Era: Should Day and Nighttime Targets be the Same?

IF 3.7 Q2 ENDOCRINOLOGY & METABOLISM
Ariana Maia, David Subias Andujar, Cristina Yuste, Lara Albert, Joana Vilaverde, Maria Helena Cardoso, Mercedes Rigla
{"title":"Time in Range Analysis in Automated Insulin Delivery Era: Should Day and Nighttime Targets be the Same?","authors":"Ariana Maia, David Subias Andujar, Cristina Yuste, Lara Albert, Joana Vilaverde, Maria Helena Cardoso, Mercedes Rigla","doi":"10.1177/19322968241236456","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hybrid closed-loop systems (HCLS) use has shown that time in range (TIR) tends to improve more during the nighttime than during the day. This study aims to compare the conventional TIR, currently accepted as 70 to 180 mg/dL, with a proposed recalculated time in range (RTIR) considering a tighter glucose target of 70 to 140 mg/dL for the nighttime fasting period in T1DM patients under HCLS.</p><p><strong>Methods: </strong>We conducted a retrospective study that included adults patients receiving treatment with Tandem t:slim X2 Control-IQ. Daytime TIR was characterized as glucose values between 70 and 180 mg/dL during the 07:01 to 23:59 time frame. Nighttime fasting TIR was specified as glucose values from 70 to 140 mg/dL between 00:00 and 07:00. The combination of the daytime and nighttime fasting glucose targets results in an RTIR, which was compared with the conventional TIR for each patient. The 14 days Dexcom G6 CGM data were downloaded from Tidepool platform and analyzed.</p><p><strong>Results: </strong>We included 22 patients with a mean age of 49.7 years and diabetes duration of 24.7 years, who had been using automatic insulin delivery (AID) HCLS for a median of 305.3 days. We verified a mean conventional TIR of 68.7% vs a mean RTIR of 60.3%, with a mean percentage difference between these two metrics of -8.4%. A significant decrease in conventional TIR was verified when tighter glucose targets were considered during the nighttime period. No significant correlation was found between the percentage difference values and RTIR, even among the group of patients with the lowest conventional TIR.</p><p><strong>Conclusions: </strong>Currently, meeting the conventional TIR metrics may fall short of achieving an ideal level of glycemic control. An individualized strategy should be adopted until further data become available for a precise definition of optimal glucose targets.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1326-1330"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571497/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968241236456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Hybrid closed-loop systems (HCLS) use has shown that time in range (TIR) tends to improve more during the nighttime than during the day. This study aims to compare the conventional TIR, currently accepted as 70 to 180 mg/dL, with a proposed recalculated time in range (RTIR) considering a tighter glucose target of 70 to 140 mg/dL for the nighttime fasting period in T1DM patients under HCLS.

Methods: We conducted a retrospective study that included adults patients receiving treatment with Tandem t:slim X2 Control-IQ. Daytime TIR was characterized as glucose values between 70 and 180 mg/dL during the 07:01 to 23:59 time frame. Nighttime fasting TIR was specified as glucose values from 70 to 140 mg/dL between 00:00 and 07:00. The combination of the daytime and nighttime fasting glucose targets results in an RTIR, which was compared with the conventional TIR for each patient. The 14 days Dexcom G6 CGM data were downloaded from Tidepool platform and analyzed.

Results: We included 22 patients with a mean age of 49.7 years and diabetes duration of 24.7 years, who had been using automatic insulin delivery (AID) HCLS for a median of 305.3 days. We verified a mean conventional TIR of 68.7% vs a mean RTIR of 60.3%, with a mean percentage difference between these two metrics of -8.4%. A significant decrease in conventional TIR was verified when tighter glucose targets were considered during the nighttime period. No significant correlation was found between the percentage difference values and RTIR, even among the group of patients with the lowest conventional TIR.

Conclusions: Currently, meeting the conventional TIR metrics may fall short of achieving an ideal level of glycemic control. An individualized strategy should be adopted until further data become available for a precise definition of optimal glucose targets.

胰岛素自动给药时代的时间范围分析:日间和夜间目标是否应该相同?
引言:混合闭环系统(HCLS)的使用表明,夜间比白天更容易改善血糖范围内时间(TIR)。本研究旨在将目前公认的 70 至 180 mg/dL 的传统 TIR 与考虑到 HCLS 系统下 T1DM 患者夜间空腹血糖目标值更严格(70 至 140 mg/dL)而提出的重新计算的范围内时间(RTIR)进行比较:我们进行了一项回顾性研究,研究对象包括接受 Tandem t:slim X2 Control-IQ 治疗的成人患者。日间 TIR 指的是 07:01 至 23:59 时间段内 70 至 180 mg/dL 的血糖值。夜间空腹 TIR 指的是 00:00 至 07:00 期间 70 至 140 mg/dL 的葡萄糖值。白天和夜间空腹血糖目标值的组合得出 RTIR,并与每位患者的传统 TIR 进行比较。从 Tidepool 平台下载 14 天的 Dexcom G6 CGM 数据并进行分析:我们纳入了 22 名患者,他们的平均年龄为 49.7 岁,糖尿病病程为 24.7 年,使用胰岛素自动给药(AID)HCLS 的时间中位数为 305.3 天。我们验证了传统 TIR 平均值为 68.7%,RTIR 平均值为 60.3%,这两个指标之间的平均百分比差异为-8.4%。当考虑在夜间期间设定更严格的血糖目标时,我们验证了常规 TIR 的大幅下降。即使在常规 TIR 值最低的一组患者中,也没有发现百分比差异值与 RTIR 之间存在明显的相关性:目前,满足常规 TIR 指标可能无法达到理想的血糖控制水平。结论:目前,达到传统的 TIR 指标可能无法实现理想的血糖控制水平,在获得更多数据以精确定义最佳血糖目标之前,应采取个体化策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Medicine-Internal Medicine
CiteScore
7.50
自引率
12.00%
发文量
148
期刊介绍: The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信